Tempest reports 100% response rate in cancer therapy trial Feb 25, 2026 07:59AM
Tempest details strategy for advancing CAR-T therapy pipeline Feb 11, 2026 06:59AM
Tempest closes acquisition of dual-targeting CAR-T assets Feb 4, 2026 04:48PM
H.C. Wainwright Upgrades Tempest Therapeutics (TPST) to Buy Jan 22, 2026 06:04AM
Tempest Therapeutics (TPST) files for 1.17M share offering by selling stockholders Dec 9, 2025 04:54PM


Nov 19, 2025 09:02AM Tempest Therapeutics announces acquisition of dual-CAR T programs
Nov 5, 2025 04:17PM Tempest Therapeutics (TPST) Misses Q3 EPS by 79c
Sep 8, 2025 07:01AM Biodexa enrolls first patients in Phase 3 trial for FAP treatment
Aug 11, 2025 04:57PM Tempest Therapeutics, Inc. (TPST) Misses Q2 EPS by 179c
Jul 28, 2025 07:00AM Biodexa initiates phase 3 trial for FAP treatment eRapa
Jun 30, 2025 08:10AM Tempest Therapeutics (TPST) Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
Jun 11, 2025 08:01AM Tempest Therapeutics (TPST) Announces 739K Share offering at $6.25/sh
Jun 5, 2025 10:28AM Tempest Therapeutics (TPST) stock rises on EMA Orphan Drug Designation
May 13, 2025 06:22PM Tempest Therapeutics, Inc. (TPST) Misses Q1 EPS by 290c
Apr 21, 2025 08:01AM Tempest Therapeutics (TPST) Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
Apr 10, 2025 06:02AM H.C. Wainwright Downgrades Tempest Therapeutics (TPST) to Neutral
Apr 9, 2025 04:30PM Tempest Therapeutics (TPST) Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
Mar 28, 2025 06:47AM Tempest Therapeutics (TPST) PT Lowered to $16 at H.C. Wainwright
Mar 13, 2025 08:00AM Tempest Therapeutics (TPST) Receives FDA Study May Proceed Notice for Phase 2 Trial of TPST-1495
Feb 10, 2025 08:00AM Tempest Therapeutics (TPST) Granted FDA Fast Track Designation for Amezalpat
Jan 6, 2025 08:03AM Tempest Therapeutics (TPST) Receives FDA Orphan Drug Designation for Amezalpat
Nov 13, 2024 09:30AM Tempest Therapeutics (TPST) PT Lowered to $5 at Piper Sandler
Nov 12, 2024 04:22PM Tempest Therapeutics, Inc. (TPST) Misses Q3 EPS by 5c
Nov 12, 2024 08:01AM Tempest Therapeutics (TPST) Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy
Oct 14, 2024 10:41AM Scotiabank Reiterates Sector Outperform Rating on Tempest Therapeutics (TPST)
Oct 11, 2024 06:39AM H.C. Wainwright Reiterates Buy Rating on Tempest Therapeutics (TPST)
Oct 10, 2024 07:01AM Tempest Therapeutics (TPST) Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Trial
Aug 21, 2024 08:02AM Tempest Therapeutics (TPST) Appoints Troy M. Wagner as VP of Quality Assurance
Aug 16, 2024 10:53AM Scotiabank Reiterates Sector Outperform Rating on Tempest Therapeutics (TPST)
Aug 15, 2024 08:00AM Tempest Therapeutics (TPST) Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat
Jul 19, 2024 04:33PM Tempest Therapeutics (TPST) Files $300M Mixed Shelf